A 17-panel drug test screens for 17 distinct substances or substance classes in a single urine sample. It covers everything on a standard 10-panel test plus several synthetic opioids, alcohol biomarkers, and nicotine. This expanded panel is commonly used in pain management programs, prenatal care, and workplaces with strict substance policies.
The 17 Substances on the Panel
Based on the standard Labcorp 17-panel configuration, the test screens for these substances:
- THC (marijuana)
- Amphetamines (including methamphetamine and MDMA/ecstasy)
- Cocaine
- Opiates (codeine, morphine)
- Oxycodone
- Fentanyl
- Tramadol
- Buprenorphine (Suboxone/Subutex)
- Tapentadol
- Methadone
- Propoxyphene
- 6-Acetylmorphine (a metabolite specific to heroin)
- Benzodiazepines (Xanax, Valium, Klonopin, and similar anti-anxiety medications)
- Barbiturates (older sedatives like phenobarbital)
- Phencyclidine (PCP)
- Ethanol biomarkers (EtG) (detects alcohol use over the previous few days, not just current intoxication)
- Nicotine metabolite (cotinine)
The inclusion of fentanyl is relatively recent. As of July 2025, updated federal guidelines from the Department of Health and Human Services officially added fentanyl to authorized workplace testing panels, reflecting how widespread synthetic opioid use has become. Many private-sector panels had already been testing for it.
How It Differs From Smaller Panels
A standard 5-panel test, the kind used for most federal and DOT-regulated jobs, covers marijuana, cocaine, amphetamines, opiates, and PCP. A 10-panel adds benzodiazepines, barbiturates, methadone, propoxyphene, and a broader opioid category. The 17-panel goes further by individually targeting synthetic and semi-synthetic opioids that standard opiate screens miss entirely.
This matters because drugs like fentanyl, tramadol, and buprenorphine are chemically different enough from natural opiates that they won’t trigger a positive on a basic opiate immunoassay. A person could be using fentanyl and pass a 5-panel test with no issue. The 17-panel closes those gaps by using separate assays for each substance. It also adds alcohol and nicotine monitoring, which smaller panels skip.
Detection Windows for Each Substance
Detection times in urine vary by substance, and they’re influenced by your metabolism, body composition, how frequently you’ve used the substance, and how concentrated your urine is. These are approximate ranges:
- THC: 1 to 30+ days (occasional use clears in a few days; daily use can linger for weeks)
- Amphetamines: 1 to 5 days
- Cocaine: 1 to 4 days
- Opiates (codeine, morphine): 1 to 4 days
- Oxycodone: 1 to 4 days
- Fentanyl: 1 to 3 days
- Tramadol: 1 to 4 days
- Buprenorphine: 1 to 7 days
- Tapentadol: 1 to 3 days
- Methadone: 1 to 14 days
- Propoxyphene: 1 to 4 days
- Heroin (6-AM): typically less than 24 hours (heroin itself metabolizes very quickly, which is why the panel also tests broader opiates)
- Benzodiazepines: 1 to 10 days, depending on the specific medication
- Barbiturates: 1 to 14 days (phenobarbital stays detectable the longest)
- PCP: 1 to 14 days for regular use
- Alcohol (EtG): 1 to 4 days
- Nicotine (cotinine): 1 to 7 days
Methadone and certain barbiturates stand out for their long detection windows. A single dose of methadone can remain detectable for up to two weeks in some cases.
Cutoff Levels and What “Positive” Means
Every substance on the panel has a concentration threshold. If the amount in your urine falls below that cutoff, the result is reported as negative, even if trace amounts are technically present. The test is designed this way to reduce false positives from incidental or passive exposure.
For marijuana, the initial screening cutoff is 50 ng/mL. If your sample hits that mark, a confirmation test looks for the specific metabolite at a tighter 15 ng/mL threshold. Cocaine’s initial screen cutoff is 150 ng/mL with a confirmatory threshold of 100 ng/mL. Fentanyl has an extremely low cutoff of just 1 ng/mL for both initial and confirmatory testing under the latest federal guidelines, reflecting how potent the drug is in small quantities.
The opiate cutoff for codeine and morphine is set high at 2,000 ng/mL. That threshold was deliberately raised in 1998 to prevent false positives from poppy seed consumption and routine prescription use.
False Positives and Cross-Reactivity
The initial screening step uses immunoassay technology, which works by detecting chemical shapes rather than exact molecules. This means structurally similar compounds can sometimes trigger a positive for something you never took.
Some common cross-reactions to be aware of: certain cold medications containing pseudoephedrine can flag for amphetamines. Some antihistamines and sleep aids have been reported to interfere with PCP and amphetamine assays. Baby wash products and certain supplements have even been documented as causing unexpected positives in rare cases.
This is why any positive result on the initial screen gets sent for confirmatory testing using mass spectrometry, a much more precise technology that identifies the exact molecular structure. Confirmed positives are highly accurate. If you have a prescription for any medication on the panel, you’ll typically have the chance to provide that documentation to a medical review officer before a result is finalized.
Instant Cups vs. Lab-Based Testing
You might encounter the 17-panel test in two formats. Instant (point-of-care) test cups give a preliminary result within minutes. These are convenient for on-site screening, but they’re less accurate than laboratory analysis. A negative on an instant cup is generally reliable, but a positive should always be confirmed by a lab.
Lab-based testing uses more sophisticated equipment, including liquid chromatography and mass spectrometry, to identify substances at much lower concentrations and with far fewer errors. Mayo Clinic Laboratories, for instance, runs its 17-drug-class panel entirely by mass spectrometry, with cutoffs as low as 2 ng/mL for fentanyl. The tradeoff is time: lab results typically take one to three business days, compared to minutes for a rapid cup.
Specimen Validity Checks
Alongside the drug screening itself, the lab checks whether your sample is legitimate. These validity tests measure creatinine concentration (to detect dilution), pH levels (to catch chemical tampering), and specific gravity. The lab also screens for oxidizing adulterants, which are chemicals sometimes added to a sample in an attempt to destroy drug metabolites. If a sample has abnormally low creatinine or a pH outside the normal range of roughly 4.5 to 9.0, it may be reported as substituted, diluted, or invalid, which typically means you’ll need to retest.